Literature DB >> 8430069

The c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus.

S Doerre1, P Sista, S C Sun, D W Ballard, W C Greene.   

Abstract

The long terminal repeat (LTR) of the type 1 human immunodeficiency virus (HIV-1) and the 5' regulatory region of the gene encoding the interleukin 2 receptor alpha subunit (IL-2R alpha) share functional kappa B enhancer elements involved in the regulation of these inducible transcription units during T-cell activation. These kappa B enhancer elements are recognized by a structurally related family of interactive proteins that includes p50, p65, and the product of the c-rel protooncogene (c-Rel). Recent biochemical studies have shown that p65 and p50 form the prototypical NF-kappa B complex, which is rapidly translocated from the cytoplasm to the nucleus during T-cell activation. This intracellular signaling complex potently stimulates kappa B-directed transcription from either the HIV-1 LTR or the IL-2R alpha promoter via the strong transactivation domain present in p65. We now demonstrate that nuclear expression of human c-Rel, which is induced by either phorbol ester or tumor necrosis factor alpha with delayed kinetics relative to p65, markedly represses p65-mediated activation of these transcription units. These inhibitory effects of c-Rel correlate with its DNA-binding activity but not with its ability to heterodimerize with p50, suggesting that c-Rel inhibition involves competition with p50/p65 for occupancy of the kappa B enhancer element. Together, these findings suggest that one function of c-Rel is as a physiologic repressor of the HIV-1 LTR and IL-2R alpha promoters, serving to efficiently counter the strong transcriptional activating effects of p65.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430069      PMCID: PMC45803          DOI: 10.1073/pnas.90.3.1023

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

3.  Cis-acting sequences responsible for the transcriptional activation of human T-cell leukemia virus type I constitute a conditional enhancer.

Authors:  H Paskalis; B K Felber; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells.

Authors:  M Kozak
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

6.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  Identification of p40x-responsive regulatory sequences within the human T-cell leukemia virus type I long terminal repeat.

Authors:  J Brady; K T Jeang; J Duvall; G Khoury
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

8.  Requirement of multiple copies of a 21-nucleotide sequence in the U3 regions of human T-cell leukemia virus type I and type II long terminal repeats for trans-acting activation of transcription.

Authors:  K Shimotohno; M Takano; T Teruuchi; M Miwa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus.

Authors:  J Sodroski; C Rosen; W C Goh; W Haseltine
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

10.  Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor.

Authors:  P A Baeuerle; D Baltimore
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

View more
  32 in total

1.  Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium.

Authors:  D M Brantley; C L Chen; R S Muraoka; P B Bushdid; J L Bradberry; F Kittrell; D Medina; L M Matrisian; L D Kerr; F E Yull
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  Regulation of c-Rel nuclear localization by binding of Ca2+/calmodulin.

Authors:  Asa Antonsson; Kate Hughes; Sofia Edin; Thomas Grundström
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

Review 3.  Molecular mechanisms in lymphocyte activation and growth.

Authors:  D W Ballard
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Identification by in vivo genomic footprinting of a transcriptional switch containing NF-kappaB and Sp1 that regulates the IkappaBalpha promoter.

Authors:  M Algarté; H Kwon; P Génin; J Hiscott
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

5.  Persistent activation of NF-kappa B/Rel by human T-cell leukemia virus type 1 tax involves degradation of I kappa B beta.

Authors:  L Good; S C Sun
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.

Authors:  A G Bassuk; R T Anandappa; J M Leiden
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  The ability of CD40L, but not lipopolysaccharide, to initiate immunoglobulin switching to immunoglobulin G1 is explained by differential induction of NF-kappaB/Rel proteins.

Authors:  S C Lin; H H Wortis; J Stavnezer
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Determinants of the establishment of human immunodeficiency virus type 1 latency.

Authors:  Alexandra Duverger; Jennifer Jones; Jori May; Frederic Bibollet-Ruche; Frederic A Wagner; Randall Q Cron; Olaf Kutsch
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription.

Authors:  Olaf Kutsch; David N Levy; Paula J Bates; Julie Decker; Barry R Kosloff; George M Shaw; W Priebe; Etty N Benveniste
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  OHMM: a Hidden Markov Model accurately predicting the occupancy of a transcription factor with a self-overlapping binding motif.

Authors:  Amar Drawid; Nupur Gupta; Vijayalakshmi H Nagaraj; Céline Gélinas; Anirvan M Sengupta
Journal:  BMC Bioinformatics       Date:  2009-07-07       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.